Hutchinson-Gilford Progeria Syndrome (HGPS): Comprehensive Research Report

1. Disease Information

Overview. Hutchinson-Gilford Progeria Syndrome (HGPS) is an ultra-rare, sporadic, autosomal dominant segmental premature-aging (progeroid) disorder of childhood caused by mutations in LMNA, the gene encoding nuclear lamins A and C. Affected children appear normal at birth but by 6–18 months of age begin to show growth failure, alopecia, joint contractures, sclerotic skin changes, and a strikingly aged facial appearance. Death occurs in the early teens (median ~14.6 years), almost always from myocardial infarction or stroke caused by accelerated, generalized atherosclerosis. HGPS is the prototypical human "laminopathy" and has become a major model for understanding both accelerated and normal cellular aging.

Key identifiers: - MONDO: MONDO:0008310 - OMIM: #176670 (phenotype); 150330 (LMNA gene) - Orphanet: ORPHA:740 - MeSH: D058495 (Progeria) - ICD-10-CM: E34.8 (other specified endocrine disorders — no dedicated code exists; often also cross-referenced informally to segmental progeroid syndromes) - ICD-11: listed under rare progeroid syndromes (LD24-group skin/connective tissue rare disease entries; no universally standardized single code — verify locally before use) - Gene: LMNA* — HGNC:6636, chromosome 1q22, Ensembl ENSG00000160789

Common synonyms: Progeria; Progeria syndrome; Hutchinson-Gilford syndrome; HGPS; "Progeria of childhood."

Evidence source note: HGPS knowledge derives predominantly from (1) aggregated disease-level clinical registries and cohort natural-history studies (The Progeria Research Foundation International Registry; the NIH-sponsored longitudinal cohort of Gordon, Merideth, and colleagues), (2) individual case reports/series (especially from the original 2003 discovery cohort), and (3) extensive mouse-model (Lmna^G609G/G609G^, Zmpste24^-/-^) and cell-based mechanistic studies. Unlike common diseases, there is essentially no large-scale EHR-derived epidemiology because the total living patient population is estimated at only ~150–400 individuals worldwide.

Sources: OMIM #176670; GeneReviews: Hutchinson-Gilford Progeria Syndrome; Orphanet ORPHA:740

2. Etiology

Disease causal factor: HGPS is a monogenic disorder caused, in ~90% of classic cases, by a recurrent de novo heterozygous silent point mutation in LMNA exon 11: c.1824C>T (p.Gly608Gly, "G608G"). This synonymous substitution does not change the encoded amino acid but activates a cryptic splice donor site, causing an internal in-frame deletion of 150 nucleotides (50 amino acids) near the C-terminus of prelamin A. The truncated protein product, progerin, retains a permanently farnesylated CAAX-motif cysteine that in wild-type prelamin A is normally removed by ZMPSTE24-mediated proteolytic processing (Eriksson et al., Nature 2003, PMID:12714972; De Sandre-Giovannoli et al., Science 2003, independently identified the same mutation). A minority of atypical/variant HGPS cases carry other LMNA exon 11 mutations that likewise increase use of the cryptic splice site (e.g., c.1968+1G>A and other splice-region variants).

"18 out of 20 classical cases of HGPS harboured an identical de novo single-base substitution, G608G (GGC>GGT), within exon 11 of the lamin A (LMNA) gene." (Eriksson et al., 2003)

Genetic risk factors: - The causal variant is essentially always de novo; there is no known population-level susceptibility allele. - Advanced paternal age at conception is a documented risk factor for the de novo germline mutation, consistent with the general paternal-age effect seen for other recurrent single-base substitutions arising in spermatogonial mitoses. - No sex or ethnic predilection has been observed for classic HGPS.

Environmental risk factors: None established — HGPS is a purely genetic, non-environmentally modified disorder, though secondary environmental exposures (UV, mechanical stress on stiffened skin/joints) may exacerbate specific phenotypic features rather than cause the disease.

Protective factors: - No genetic protective/modifier variants have been robustly established in humans. - In mouse models, genetic reduction of mTOR signaling, rapamycin/everolimus treatment, and pharmacologic inhibition of progerin farnesylation (farnesyltransferase inhibitors) partially rescue phenotypes and extend survival — these represent pharmacologic rather than heritable protective factors (Cabral et al., Aging Cell 2021, mTOR reduction extends lifespan in HGPS mouse model).

Gene-environment interactions: Because progerin production and its farnesylation status are biochemically fixed by the mutation, there is little evidence for meaningful gene-environment interaction modulating penetrance; the near-complete penetrance and stereotyped course argue against major environmental modifiers.

Sources: Eriksson et al. Nature 2003; GeneReviews; Cabral et al. Aging Cell 2021

3. Phenotypes

HGPS phenotypes span nearly every organ system. Below, phenotypes are grouped by type with onset, severity/progression, frequency, and suggested HPO terms.

Growth / General

Dermatologic

Craniofacial

Musculoskeletal

Cardiovascular (dominant cause of mortality)

Other

• High-pitched voice — HP:0001620
• Low-frequency conductive hearing loss — HP:0000405
• Dry eyes / exposure keratitis — HP:0100530
• Normal cognitive/motor development — a critical distinguishing negative feature; intelligence is preserved (HP:0000750 explicitly absent — this is a key differential point).

Progression/course: Phenotype is progressive and cumulative rather than static, with near-complete penetrance of the core phenotypic gestalt. Severity is broadly stereotyped across patients (low inter-individual variance compared with most Mendelian disorders), though atypical/variant LMNA mutations produce milder, later-onset, or asymmetric ("mosaic") phenotypes.

Quality of life impact: Joint contractures and hip disease progressively limit mobility; dental crowding/delayed eruption complicates feeding and oral hygiene; skin fragility and lipodystrophy predispose to pressure injury; hearing loss and dry eyes affect communication/comfort. Cognitive and emotional development is normal, so QoL burden is heavily weighted toward physical disability and the psychosocial impact of visible difference and a foreshortened, medically intensive life course; dedicated EQ-5D/SF-36 HGPS-specific QoL instruments are not established in the literature (an evidence gap).

Sources: Merideth et al., NEJM 2008 "Phenotype and Course of Hutchinson-Gilford Progeria Syndrome"; GeneReviews; OMIM Clinical Synopsis #176670

4. Genetic/Molecular Information

Causal gene: LMNA (HGNC:6636; OMIM *150330), chr1q22, encoding lamin A and lamin C via alternative splicing of a shared pre-mRNA.

Pathogenic variant (classic HGPS): - c.1824C>T; p.Gly608Gly (silent at the protein level for full-length lamin A but pathogenic via cryptic splicing) — accounts for ~90% of clinically diagnosed HGPS. - Additional/atypical variants: other exon-11 substitutions and splice-region variants (e.g., c.1968+1G>A) that likewise activate/strengthen the same or a nearby cryptic 5′ splice site, producing progerin or progerin-like transcripts, sometimes with different truncation lengths (associated with atypical, often milder, later-onset phenotypes — sometimes termed "atypical Werner syndrome" or "atypical progeroid syndrome" when overlapping with Werner-like features). - Variant classification: Pathogenic per ACMG/AMP criteria (recurrent de novo, functional splicing data, gain-of-toxic-function mechanism); listed in ClinVar under LMNA-related progeria. - Population frequency: Effectively absent from gnomAD/1000 Genomes/ExAC/TOPMed reference populations (consistent with near-complete de novo origin and lethality before reproduction — no evolutionary/selective persistence). - Origin: Germline de novo in ~98% of cases; ~2% arise from unaffected parental germline (gonadal) mosaicism, raising empiric sibling recurrence risk to roughly 1 in 500 (vs. the population birth incidence of ~1 in 4–8 million) once one affected mosaic-transmitting parent is identified. - Functional consequence: Dominant-negative/toxic gain-of-function — progerin is not merely loss of lamin A function but an actively toxic, permanently farnesylated, membrane-anchored aberrant protein that structurally disrupts the nuclear lamina meshwork (dominant-negative interference with normal lamin A/C and B-type lamin network assembly).

Modifier genes: No confirmed human genetic modifiers of HGPS severity have been established; the karyotypically stereotyped phenotype across patients argues for limited modifier-gene effect, though the ratio of progerin:normal lamin A/C transcript (influenced by splicing efficiency) modifies severity, as seen in "neonatal progeria" cases with an unusually high progerin:lamin-A ratio causing a fulminant perinatal-onset phenotype (Reddy & Comai, EJHG 2012).

Epigenetic information: HGPS cells show global heterochromatin loss — reduced trimethylation of H3K9 (H3K9me3) and H3K27me3, loss of heterochromatin protein 1 (HP1), altered DNA methylation patterns, and a distorted "epigenetic clock" (accelerated Horvath/Hannum methylation age). Phosphorylated Lamin A/C mislocalizes to the nuclear interior and binds active enhancers, driving abnormal transcriptional programs (bioRxiv preprint, Nature-affiliated work on progeria enhancer binding).

Chromosomal abnormalities: None — HGPS is a single-nucleotide-variant disorder, not a copy-number/structural chromosomal condition.

Related genes for the broader laminopathy spectrum (for differential diagnosis/module cross-reference): ZMPSTE24 (HGNC:16063, OMIM 606480) — encodes the zinc metalloprotease responsible for the second proteolytic cleavage step maturing prelamin A to lamin A; biallelic loss-of-function mutations cause Restrictive Dermopathy (lethal) and Mandibuloacral Dysplasia type B*, both "secondary laminopathies" mechanistically related to HGPS via farnesylated-prelamin-A accumulation, though — importantly — mouse data show farnesyl-prelamin-A (Zmpste24-null) and progerin (Lmna-G609G) differ in their capacity to cause vascular smooth muscle cell (VSMC) loss, with progerin being uniquely and progressively pathogenic to the vasculature (see Section 6).

GO/HGNC term suggestions: - Gene: hgnc:6636 (LMNA) - GO:0005637 (nuclear inner membrane), GO:0005652 (nuclear lamina), GO:0016233 (telomere capping), GO:0006357 (regulation of transcription by RNA Pol II)

Sources: Eriksson et al. Nature 2003, PMID:12714972; GeneReviews; Reddy & Comai, EJHG 2012 "Neonatal progeria"

5. Environmental Information

HGPS has no known environmental, infectious, lifestyle, or toxin-based causal contribution — it is a purely genetic disorder driven by a recurrent de novo germline point mutation. There is no infectious agent, occupational exposure, dietary factor, or teratogen implicated in disease causation. The only quasi-"environmental" association identified in the literature is advanced paternal age, which increases the background rate of de novo germline point mutations generally (including this one), operating through normal spermatogonial mutation accumulation rather than an exogenous exposure.

Secondary environmental modifiers affect symptom management rather than etiology: skin fragility increases vulnerability to pressure injury/trauma; joint contractures and reduced subcutaneous fat increase risk of cold intolerance and skin breakdown; and reduced bone density increases fracture risk with minor trauma.

6. Mechanism / Pathophysiology

Causal chain overview:

1. Molecular trigger: LMNA c.1824C>T activates a cryptic splice donor in exon 11 → internally truncated prelamin A transcript lacking 150 nt (50 aa), including the second endoproteolytic (ZMPSTE24) cleavage site.
2. Protein consequence: The translated protein, progerin, undergoes the first (farnesylation) but not the second (defarnesylating cleavage) post-translational maturation step, so it remains permanently farnesylated and constitutively membrane-anchored (GO:0018343 protein farnesylation).
3. Nuclear lamina disruption: Progerin incorporates into and disrupts the nuclear lamina meshwork (a dominant-negative effect on normal lamin A/C and lamin B networks) → abnormal, "blebbed"/lobulated nuclear morphology, altered nuclear stiffness and mechanotransduction, and nuclear envelope rupture under mechanical stress.
4. Downstream nuclear consequences:
5. Loss of peripheral heterochromatin (reduced H3K9me3, H3K27me3, HP1) and altered spatial genome organization (disrupted lamina-associated domains, LADs)
6. Accumulation of unrepaired DNA damage and impaired DNA-damage-response signaling (reduced 53BP1/ATM recruitment efficiency)
7. Telomere dysfunction/shortening and replicative senescence
8. Mislocalization of phosphorylated lamin A/C to active enhancers, driving aberrant transcriptional output
9. Impaired nucleocytoplasmic transport and mitotic defects
10. Cellular consequences: Premature cellular senescence (this module overlaps mechanistically with the dismech cellular_senescence module — p16INK4a/p21 arrest pathways are activated in HGPS fibroblasts and vascular cells), increased apoptosis under mechanical/oxidative stress, impaired proliferative capacity, and stem/progenitor cell exhaustion.
11. Tissue/organ consequences — cardiovascular (dominant mortality driver): In vascular smooth muscle cells (VSMCs), progressive age-dependent progerin accumulation (unlike static farnesyl-prelamin-A in the related Zmpste24-null model) causes massive VSMC loss in the aortic media, triggering compensatory but maladaptive remodeling: adventitial fibrosis, extracellular matrix deposition, arterial stiffening, and accelerated atherosclerotic plaque formation — clinically culminating in myocardial infarction and stroke (this pathway conceptually parallels the dismech atherogenesis module, substituting progerin-driven VSMC depletion for the classical LDL-retention/foam-cell trigger, and also intersects thrombogenesis at the plaque-rupture endpoint).
12. Other organ systems: Osteoblast/osteoclast dysregulation and growth-plate abnormalities → osteoporosis/osteolysis (parallels osteoporosis_bone_resorption); adipocyte progenitor dysfunction → severe lipodystrophy; dermal fibroblast senescence → sclerodermatous skin change and alopecia via hair-follicle stem cell/dermal papilla dysfunction.

Molecular pathways (KEGG/Reactome/GO): - Nuclear lamina organization: GO:0007084 (mitotic nuclear envelope reassembly), GO:0034399 (nuclear periphery), GO:0000785 (chromatin) - DNA damage response: GO:0006281 (DNA repair), GO:0000077 (DNA damage checkpoint) - Farnesylation/isoprenoid pathway (mevalonate pathway) — CHEBI:44468 (farnesyl group), CHEBI:15339 (farnesyl-PP), relevant to farnesyltransferase-inhibitor mechanism (see Treatment) - mTOR signaling (GO:0031929, TOR signaling) — implicated via autophagy impairment; genetic/pharmacologic mTOR reduction (rapamycin/everolimus) improves autophagic clearance of progerin and extends mouse lifespan.

Cell types involved (CL terms): - CL:0000186 (myofibroblast)/dermal fibroblast (CL:0002620) — sclerodermatous skin - CL:0000359 (vascular smooth muscle cell, CL:0000359) — progressive loss, central to cardiovascular pathology - CL:0000058 (chondrocyte) and osteoblast (CL:0000062)/osteoclast (CL:0000092) — skeletal disease - CL:0000138 (chondrocyte, growth plate) — growth-plate morphology abnormalities - Endothelial cells (CL:0000115) — impaired mechanoresponse to shear stress, contributing to vascular pathology

Anatomical/tissue involvement: See Section 7.

Single-cell/omics findings: Single-cell and bulk transcriptomic studies of HGPS fibroblasts and iPSC-derived VSMCs consistently show senescence-associated secretory phenotype (SASP) gene upregulation, dysregulated cell-cycle genes, extracellular matrix remodeling genes, and inflammatory signaling (NF-κB pathway activation) — organ-specific inflammatory/fibrotic transcriptomic signatures have been characterized in the Lmna^G609G^ mouse across multiple organs (2024 "Inflammation and Fibrosis in Progeria" study).

Model-organism mechanistic evidence caveat (HUMAN_MODEL_MISMATCH-relevant): The Zmpste24^-/-^ mouse (which accumulates farnesylated full-length prelamin A rather than progerin) does not reproduce the VSMC-loss/vascular phenotype seen in the Lmna^G609G^ progerin-expressing model or in human HGPS, despite equivalent nuclear-lamina disruption at the cellular level — indicating that progerin's specific, progressively accumulating molecular identity (not merely permanent farnesylation generically) drives the clinically dominant cardiovascular phenotype. This is a mechanistically important human-model fidelity nuance for any pathophysiology curation.

Sources: Kang et al./Villa-Bellosta lab, "Vascular smooth muscle cell loss underpins accelerated atherosclerosis," PMC6527384; "The accumulation of progerin underlies the loss of aortic smooth muscle cells," Cell Death & Disease 2025, PMID:40707465; Frontiers, "Are There Common Mechanisms Between HGPS and Natural Aging?", PMC6529819; Cabral et al., Aging Cell 2021

7. Anatomical Structures Affected

Organ level: - Primary: Skin/subcutaneous tissue (UBERON:0002097 skin), skeletal system (UBERON:0001434 bone), cardiovascular system (UBERON:0001981 blood vessel; UBERON:0000948 heart), adipose tissue (UBERON:0001013) - Secondary/complications: Central nervous system (stroke secondary to cerebrovascular atherosclerosis — UBERON:0001017 CNS), inner/middle ear (conductive hearing loss — UBERON:0001846 middle ear), eye (lagophthalmos, dry eye — UBERON:0000970 eye), dentition (UBERON:0001091 tooth) - Body systems: Integumentary, musculoskeletal, cardiovascular, and — secondarily — auditory and ophthalmologic systems. Endocrine/metabolic involvement includes lipodystrophy-associated insulin resistance in some patients.

Tissue/cell level: - Dermis and subcutis: dermal fibroblasts, adipocytes (progressive loss) - Arterial wall (tunica media): vascular smooth muscle cells (progressive depletion), adventitial fibroblasts (compensatory fibrosis) - Bone: osteoblasts, osteoclasts, growth-plate chondrocytes - Hair follicle: follicular stem cells/dermal papilla (alopecia) - Cardiac tissue: cardiomyocytes (secondary structural/functional changes from chronic pressure/ischemia)

Subcellular level (GO Cellular Component): - GO:0005638 (lamin filament) / GO:0005652 (nuclear lamina) — primary site of the molecular lesion - GO:0005637 (nuclear inner membrane) — progerin's farnesyl-anchored membrane association - GO:0000785 (chromatin) — heterochromatin loss - GO:0005657 (replication fork) — replication stress

Localization: Systemic/generalized rather than focal — vascular disease is diffuse (coronary, cerebral, and peripheral arteries all affected), skin change is generalized (though most pronounced over the abdomen and extremities), and skeletal disease affects multiple joints (hips, clavicles, distal phalanges) rather than a single site. No meaningful lateralization is reported — the disease is symmetric/bilateral throughout.

8. Temporal Development

Onset: Congenital genetic lesion, but clinically silent at birth; the first recognizable features (growth deceleration, localized scleroderma-like skin change, subtle alopecia) emerge between 6 and 18 months of age (median age at clinical diagnosis ~19 months, per Orphanet). Onset pattern is insidious and progressive, not acute.

Progression: Disease has no formal staged classification (unlike, e.g., cancer staging), but natural-history literature describes a continuously progressive course: - Early stage (infancy–early childhood): Growth failure, alopecia onset, early skin changes, subclinical vascular disease begins. - Intermediate stage (childhood): Joint contractures, osteoporosis/osteolysis, characteristic facial gestalt fully established, progressive arterial stiffening and early atherosclerotic changes become detectable by imaging. - Advanced/end-stage (adolescence): Severe generalized atherosclerosis, cardiac dysfunction, and terminal cardiovascular events (myocardial infarction, stroke).

Progression rate: Rapid relative to normal human aging — HGPS compresses cardiovascular aging that normally unfolds over 70–80 years into roughly 12–15 years, giving the disease its "accelerated aging" designation, though it is important to note HGPS is a segmental progeroid syndrome (not all aging phenotypes are recapitulated — e.g., cognition, cataracts, and cancer risk are largely spared).

Disease course pattern: Progressive, non-remitting, non-episodic; there is no spontaneous remission.

Disease duration: Chronic and lifelong from clinical onset; median survival is approximately 13–14.6 years (Orphanet cites median life expectancy 13 years; more recent registry data from the treatment era report mean age at death of 14.6 years).

Critical periods: Early childhood represents a key intervention window — farnesyltransferase inhibitor therapy is now recommended to begin as early as possible after diagnosis, since vascular disease begins accumulating (subclinically) from early childhood; the base-editing gene-correction mouse work likewise showed maximal benefit when treatment (AAV9-ABE) was given at postnatal day 14, well before overt phenotype onset — suggesting an analogous "early therapeutic window" hypothesis in humans (not yet clinically validated — a HUMAN_MODEL_MISMATCH-flaggable translational gap).

9. Inheritance and Population

Epidemiology: - Birth incidence: ~1 in 4 million births (some sources cite 1 in 8 million live births — estimates vary by registry methodology) - Point prevalence: <1 per 1,000,000 (worldwide); ~1 in 20 million living individuals - Total known living patients worldwide: ~150–400 (estimates vary by year/registry ascertainment)

Inheritance pattern: Autosomal dominant (HP:0000006), but de novo in ~98% of cases — sporadic occurrence, not typically transmitted from an affected parent (survival to reproductive age is essentially never observed without treatment given the severe pre-teen mortality).

Penetrance: Complete/high penetrance for the classic phenotype once the pathogenic variant is present.

Expressivity: Relatively consistent for the classic G608G mutation; variable and generally milder for atypical splice-site variants (variable expressivity across the LMNA-associated progeroid spectrum).

Genetic anticipation: Not applicable — this is not a repeat-expansion disorder.

Germline mosaicism: Documented in a small number of families; recurrence risk for parents of an affected child is empirically estimated at up to ~1 in 500 (vs. baseline population risk of ~1 in 4–8 million), reflecting rare parental gonadal/somatic mosaicism for the mutation.

Founder effects: None reported — the mutation arises recurrently and independently (a true recurrent de novo mutation hotspot at a CpG-adjacent site), not through a shared ancestral founder haplotype.

Consanguinity: Not a relevant risk factor for classic (dominant, de novo) HGPS; may be relevant for the recessive related laminopathies (Restrictive Dermopathy, Mandibuloacral Dysplasia type B via ZMPSTE24) which do show consanguinity-associated enrichment.

Carrier frequency: Not applicable in the traditional sense (dominant, de novo, non-carrier-screened condition); population allele frequency is essentially zero in reference databases (gnomAD).

Population demographics: - Affected populations: Reported across all continents and ethnic groups with no clear predilection; the Progeria Research Foundation registry includes patients from >40 countries. - Geographic distribution: No endemic clustering; cases are sporadic and globally distributed (consistent with recurrent de novo mutation rather than an inherited founder allele). - Sex ratio: Approximately equal (no significant male:female skew reported in large series). - Age distribution: By definition, a pediatric/adolescent disease — nearly all living patients are children, adolescents, or rarely young adults (survival into the third decade is exceptional even with treatment).

Sources: Orphanet ORPHA:740; GeneReviews

10. Diagnostics

Clinical diagnosis: HGPS is primarily a clinical diagnosis based on the recognizable gestalt (growth failure + alopecia + sclerodermatous skin + characteristic facies + joint contractures), confirmed by molecular genetic testing.

Laboratory tests / biomarkers: - Lipid panel (often shows dyslipidemia contributing to atherogenesis) - Elevated urinary hyaluronic acid has historically been reported as a nonspecific biomarker of connective tissue turnover in some progeroid syndromes (older literature; low specificity) - No FDA-qualified circulating biomarker of progerin burden is in routine clinical use, though research assays quantifying progerin mRNA/protein in skin fibroblasts or PBMCs are used investigationally as pharmacodynamic trial endpoints.

Imaging studies: - Echocardiography — annual assessment of cardiac function, valve status (aortic stenosis has been specifically reported as a complication requiring intervention), and structural changes. - Carotid/vascular ultrasound and MRA of head/neck vessels — annual surveillance for arterial narrowing/stroke risk. - Skeletal radiographs — for osteolysis (acral, clavicular), coxa valga, hip dislocation. - Cardiac MRI — for detailed structural/functional assessment in specialized centers. - Dual-energy X-ray absorptiometry (DEXA) — bone mineral density monitoring for osteoporosis.

Functional tests: - Electrocardiogram (annual) — for conduction abnormalities/prolonged QRS. - Pulse-wave velocity / arterial stiffness measures — increasingly used as a research and clinical surveillance tool for vascular disease progression.

Genetic testing: - Single-gene sequencing of LMNA exon 11 (targeted Sanger sequencing) is the standard confirmatory test, given the recurrent, highly specific c.1824C>T mutation accounting for ~90% of cases. - Broader laminopathy/progeroid gene panels (including LMNA, ZMPSTE24, BANF1, POLD1, WRN) are used when the phenotype is atypical or when classic HGPS testing is negative. - Whole-exome/genome sequencing is appropriate for atypical presentations without a clear clinical HGPS gestalt, or when panel testing is unrevealing. - Chromosomal microarray/karyotype are not informative for HGPS (single-nucleotide-level lesion) but may be used to exclude alternative differential diagnoses. - Prenatal/preimplantation genetic testing is available once the familial variant is known (relevant chiefly for families with documented germline mosaicism).

Clinical diagnostic criteria: No single validated formal consensus scoring system analogous to Ghent (Marfan) exists in wide clinical use, though the classic gestalt (Merideth et al. 2008; GeneReviews) functions as an informal diagnostic framework: growth failure + alopecia + skin changes + characteristic facies + joint disease, with genetic confirmation required to establish diagnostic certainty and rule out phenocopies.

Differential diagnosis: Other progeroid syndromes — Néstor-Guillermo progeria syndrome (BANF1), Werner syndrome (WRN, adult-onset), Cockayne syndrome, Mandibuloacral Dysplasia, Restrictive Dermopathy, Wiedemann-Rautenstrauch (neonatal progeroid) syndrome, and acrogeria; distinguishing features include age of onset, presence/absence of intellectual disability, and specific skeletal/skin findings.

Screening: No population-based newborn screening exists (extreme rarity, no treatable pre-symptomatic window currently validated at scale), though early recognition of the classic gestalt in infancy prompts urgent genetic confirmation given the availability of disease-modifying therapy (lonafarnib).

Sources: GeneReviews; "Intervention for critical aortic stenosis in HGPS," PMC11079313

11. Outcome/Prognosis

Survival/mortality: - Untreated median survival: ~13 years (Orphanet); mean age at death historically cited around 13 years, more recent registry cohorts (which include treated patients) report mean age at death of 14.6 years. - Cause of death: Overwhelmingly cardiovascular — myocardial infarction and stroke secondary to accelerated, generalized atherosclerosis are the leading causes in >75% of deaths. - Lonafarnib treatment effect on survival: In the pivotal JAMA 2018 analysis (Gordon et al., comparing treated vs. untreated cohorts with up to 11 years follow-up), lonafarnib treatment was associated with a survival benefit of approximately 2.5 years relative to untreated historical controls.

Morbidity/functional outcomes: - Progressive joint contractures and hip disease cause increasing mobility limitation over the disease course, often necessitating assistive devices, bracing, or surgery. - Growth failure results in very short stature and low weight persisting throughout life. - Hearing loss (conductive) and dental crowding/malocclusion contribute to communication and nutritional challenges. - Cognitive/intellectual development remains normal throughout — a key prognostic distinguishing feature from many other progeroid/neurodevelopmental syndromes.

Disease course / complications: - Aortic/mitral valve calcification and stenosis have been reported as a later complication requiring surgical or transcatheter intervention in some cases. - Progressive osteolysis (clavicular, acral) and osteoporosis increase fracture risk. - Recurrent minor infections are not a prominent feature (immune function is largely preserved), distinguishing HGPS from progeroid syndromes with immunodeficiency components.

Prognostic factors: Earlier initiation and longer duration of farnesyltransferase-inhibitor therapy correlate with greater survival benefit in registry analyses; degree of baseline vascular stiffness/carotid-femoral pulse-wave velocity at treatment initiation has been explored as a prognostic/pharmacodynamic marker in clinical trials.

Sources: Gordon LB et al., JAMA 2018 "Association of Lonafarnib Treatment vs No Treatment With Mortality Rate"; Orphanet ORPHA:740

12. Treatment

Pharmacotherapy — Approved

Lonafarnib (Zokinvy®) — a farnesyltransferase inhibitor (FTI), FDA-approved November 2020 — is the only approved disease-modifying therapy, indicated for HGPS and certain processing-deficient progeroid laminopathies in patients ≥1 year old. - Mechanism: Inhibits farnesyltransferase, thereby blocking the initial farnesylation step of prelamin A/progerin maturation, reducing progerin's membrane anchoring and its disruptive incorporation into the nuclear lamina. - Efficacy: Registry-based comparison (Gordon et al., JAMA 2018) showed a ~2.5-year survival benefit with up to 11 years follow-up; earlier trial data (Gordon et al., Circulation 2016 triple-therapy trial, PMID:27400896) established cardiovascular/bone benefit signals. - Adverse events: Nausea, vomiting, diarrhea, increased appetite, fatigue (generally manageable/tolerable in pediatric populations). - MAXO/NCIT terms: treatment_term NCIT:C15986 (Pharmacotherapy); therapeutic_agent CHEBI or NCIT term for lonafarnib (NCIT:C71892 Lonafarnib, if available in local ontology — verify via OAK).

Pharmacotherapy — Combination trials (historical)

• Triple therapy (lonafarnib + pravastatin + zoledronic acid): NCT00879034/NCT00916747 (Gordon et al., Circulation 2016, PMID:27400896) — showed additional bone mineral density benefit from adding pravastatin/zoledronic acid, but no added cardiovascular benefit beyond lonafarnib monotherapy, suggesting lonafarnib is the principal survival-driving agent.
• Lonafarnib + everolimus (rapamycin analog): Phase 1 (completed 2017) / Phase 2 (completed 2022), 60 children from 27 countries — targets autophagic clearance of progerin as an adjunct mechanism to farnesylation inhibition.

Advanced/Experimental Therapeutics

• Gene editing (adenine base editing): In vivo adenine base editor (ABE) delivered via AAV9 corrected the pathogenic Lmna mutation in a mouse model, rescuing vascular pathology and extending median lifespan from 215 to 510 days after a single postnatal-day-14 injection (Koblan/Levy/Liu et al., Nature 2021, PMID:33408413) — proof-of-concept for a potential one-time curative gene-correction approach, not yet in human trials.
• Antisense oligonucleotide (ASO) approaches: Morpholino ASOs targeting the aberrant exon-11 cryptic splice site have shown preclinical efficacy in reducing progerin production (splice-modulation mechanism analogous to the dismech antisense_oligonucleotide_therapy module's splice-redirection paradigm) — preclinical stage.
• Progerinin: A small molecule optimized to inhibit progerin-lamin A binding; extended mouse lifespan by 10–14 weeks (more effective than lonafarnib in that model); FDA authorized Phase 2a trial enrollment at Boston Children's Hospital (announced October 2024) — an active experimental therapeutic as of the current reporting window.
• Isoprenylcysteine carboxylmethyltransferase (ICMT) inhibition: An alternative post-translational-processing target explored preclinically as a farnesylation-pathway-adjacent strategy.
• Senolytics (dasatinib, quercetin, fisetin): Explored in Zmpste24^-/-^ progeria mouse models; fisetin specifically showed efficacy in attenuating bone degeneration — preclinical, not yet in HGPS human trials.

Supportive/Rehabilitative Care

• Multidisciplinary management (pediatrics, cardiology, orthopedics, dermatology, dentistry, physical/occupational therapy, nutrition, audiology, ophthalmology).
• Cardiology surveillance: Annual echocardiogram, ECG, blood pressure, lipid panel; annual brain MRI/MRA for cerebrovascular narrowing.
• Physical/occupational therapy: For joint contractures; bracing or reconstructive hip surgery for hip dislocation (MAXO:0000011 physical therapy; NCIT:C15302).
• Nutritional support: High-calorie, nutrient-dense diet given growth failure and lipodystrophy (MAXO:0000088 dietary intervention).
• Dental care: Ongoing management of delayed/crowded dentition.
• Cardiac/vascular intervention: Case reports describe surgical or transcatheter intervention for critical aortic stenosis when it develops.

Treatment strategy

Current standard of care is lonafarnib initiated as early as possible after diagnosis, combined with lifelong multidisciplinary supportive/surveillance care; combination and gene-correction/ASO/small-molecule strategies represent the active experimental frontier (registered on ClinicalTrials.gov and via the Progeria Research Foundation's clinical trials program).

Sources: FDA approval summary, Genetics in Medicine 2022; Gordon et al., Circulation 2016, PMID:27400896; Koblan et al., Nature 2021, PMID:33408413; Progerinin, Communications Biology 2020; BioSpace, Progerinin Phase 2a authorization

13. Prevention

Primary prevention: Not applicable in the traditional sense (no modifiable environmental/lifestyle cause); the only "primary prevention" lever is avoidance of transmission in the rare setting of known parental germline mosaicism, via reproductive options below.

Secondary prevention (early detection): Early clinical recognition of the HGPS gestalt in infancy, prompting rapid genetic confirmation, is the key "secondary prevention" strategy — enabling earlier initiation of lonafarnib, which registry data associate with greater survival benefit.

Tertiary prevention: Structured multidisciplinary surveillance (annual cardiology, vascular imaging, DEXA, dental, audiology, ophthalmology assessments — see Section 12) aims to prevent/delay complications (stroke, critical valve stenosis, fracture) rather than the underlying disease process.

Genetic counseling: Central to family management — given the ~98% de novo origin, recurrence risk for parents of an affected child is population-level low, but the possibility of germline mosaicism (empiric recurrence risk up to ~1 in 500) warrants offering prenatal diagnosis or preimplantation genetic testing (PGT) once the familial LMNA variant is confirmed, particularly for future pregnancies in families with an affected child.

Screening programs: No newborn or population genetic screening program exists for HGPS given its extreme rarity and current lack of a presymptomatic-detection-driven early-intervention protocol validated at a population level.

Immunization: Not disease-specific; standard pediatric immunization schedules apply (immune competence is preserved in HGPS).

14. Other Species / Natural Disease

Taxonomy: No naturally occurring HGPS-equivalent disease has been documented in non-human species (NCBI Taxon Homo sapiens: NCBITaxon:9606). Unlike some Mendelian disorders with veterinary natural-disease counterparts (e.g., in dogs), HGPS is not known to occur spontaneously in companion animals or wildlife.

Orthologous gene: Lmna is highly conserved across mammals (mouse Lmna: MGI:96799; NCBI Gene). The equivalent murine mutation (c.1827C>T; p.Gly609Gly, "G609G") has been engineered as a knock-in model (see Section 15) rather than arising naturally.

Comparative biology: The lamin A processing pathway (farnesylation → ZMPSTE24 cleavage → mature lamin A) is conserved from mammals broadly; the fundamental biology of progerin toxicity (nuclear lamina disruption, heterochromatin loss, senescence induction) is evolutionarily conserved and recapitulated across engineered mouse, and to a lesser degree engineered zebrafish/C. elegans, systems — though no species has a naturally occurring/spontaneous equivalent.

Zoonotic potential: Not applicable — HGPS is a non-transmissible genetic disorder.

15. Model Organisms

Mouse models (the dominant HGPS model system):

1. Lmna^G609G^ knock-in mouse (equivalent to human c.1824C>T/G608G) — the flagship, most widely used HGPS model.
2. Heterozygous (Lmna^G609G/+^): Normal until ~24 weeks, then progressive progeroid phenotype, death at a mean age of ~35 weeks — models a milder/slower disease course.
3. Homozygous (Lmna^G609G/G609G^): More severe/earlier phenotype — osteoporosis, loss of fat depots, VSMC depletion, aberrant hormonal profiles (hypoglycemia), death at 14–15 weeks.
4. Cardiovascular recapitulation: Prolonged QRS intervals, progressive VSMC loss, arterial stiffening, reduced ejection fraction/fractional shortening, diastolic dysfunction — closely mirrors the dominant human cardiovascular mortality driver.

5. Musculoskeletal recapitulation: Decreased isometric tetanic torque, muscle atrophy, fibrosis; altered growth-plate morphology (though normal bone matrix mineralization has been specifically noted as a point of partial non-recapitulation in some sub-analyses — a nuance for translational fidelity assessment).

6. G608G BAC transgenic mouse — expresses the human mutant LMNA transgene; shows cardiac and skeletal muscle manifestations analogous to human disease (Hong et al., Aging Cell 2024).

7. Zmpste24^-/-^ knockout mouse — models the related "secondary laminopathy" mechanism (farnesyl-prelamin-A accumulation from failure of the second processing cleavage, rather than progerin production per se). Useful for isolating the farnesylation/lamina-disruption mechanism from progerin-specific pathology; notably this model does not reproduce the VSMC-loss/vascular phenotype to the same degree as the progerin-expressing G609G model even at later ages, an important model-fidelity distinction (a candidate HUMAN_MODEL_MISMATCH flag if used to model human HGPS vascular disease specifically).

8. Genetic/pharmacologic intervention models: mTOR-reduction (genetic or rapamycin/everolimus) crosses with the G609G model extend lifespan (Cabral et al., Aging Cell 2021); AAV9-delivered adenine base editor treatment of G609G-model mice (Koblan et al., Nature 2021) achieved the most dramatic lifespan extension reported to date (215→510 days median).

Cellular/in vitro models: - Patient-derived dermal fibroblasts (the original and still most widely used HGPS cellular model) — recapitulate dysmorphic nuclei, heat-stress hypersensitivity, senescence markers. - iPSC-derived vascular smooth muscle cells and endothelial cells from HGPS patients — used to study progerin's cell-autonomous effects on vascular mechanobiology (e.g., impaired adaptation to shear stress). - CRISPR-engineered isogenic cell lines carrying the G608G mutation — used for mechanistic dissection and drug-screening.

Applications: Mouse and cellular models have been essential for (a) establishing the vascular smooth muscle cell loss mechanism, (b) preclinical testing of farnesyltransferase inhibitors, mTOR inhibitors, progerinin, ASOs, and base-editing gene correction, and (c) exploring the progerin/normal-aging mechanistic overlap hypothesis.

Limitations: Mouse models generally show a compressed but qualitatively similar disease course; some human-specific features (e.g., precise skeletal dysplasia patterns, dental phenotype) are imperfectly or only partially recapitulated, and — as above — the specific choice between progerin-expressing (G609G) vs. farnesyl-prelamin-A-accumulating (Zmpste24-null) models materially changes which phenotypes (especially vascular) are captured, an important caveat for interpreting any single model's translational relevance.

Resources: MGI (Mouse Genome Informatics) records for Lmna; the Progeria Research Foundation maintains a Cell and Tissue Bank distributing patient-derived fibroblast lines to researchers.

Sources: "Long term breeding of the Lmna G609G progeric mouse," PMID:31794853; Hong et al., Aging Cell 2024; "Vascular smooth muscle cell loss underpins accelerated atherosclerosis in HGPS," PMC6527384; Cabral et al., Aging Cell 2021

Summary Ontology Term Quick-Reference

Key Evidence Citations (PMID/DOI)

• Eriksson M, et al. "Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndrome." Nature 2003;423:293–298. PMID:12714972
• Merideth MA, et al. "Phenotype and Course of Hutchinson–Gilford Progeria Syndrome." N Engl J Med 2008;358:592–604.
• Gordon LB, et al. "Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome." Circulation 2016. PMID:27400896
• Gordon LB, et al. "Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome." JAMA 2018;319(16):1687–1695.
• Koblan LW, et al. "In vivo base editing rescues Hutchinson–Gilford progeria syndrome in mice." Nature 2021;589:608–614. PMID:33408413
• Cabral WA, et al. "Genetic reduction of mTOR extends lifespan in a mouse model of Hutchinson-Gilford Progeria syndrome." Aging Cell 2021. PMID:34519171 (verify)
• "The accumulation of progerin underlies the loss of aortic smooth muscle cells in Hutchinson-Gilford progeria syndrome." Cell Death & Disease 2025. PMID:40707465
• Reddy S, Comai L. "Neonatal progeria: increased ratio of progerin to lamin A leads to progeria of the newborn." Eur J Hum Genet 2012.

Sources

• OMIM #176670 — Hutchinson-Gilford Progeria Syndrome
• OMIM Clinical Synopsis #176670
• GeneReviews: Hutchinson-Gilford Progeria Syndrome
• Orphanet ORPHA:740
• Eriksson et al., Nature 2003 / PubMed
• Merideth et al., NEJM 2008
• Gordon et al., Circulation 2016 / PubMed
• Gordon et al., JAMA 2018 (full article)
• FDA approval summary for lonafarnib (Zokinvy), Genetics in Medicine 2022
• Koblan et al., Nature 2021 (base editing) / PubMed
• Vascular smooth muscle cell loss underpins accelerated atherosclerosis in HGPS, PMC6527384
• The accumulation of progerin underlies loss of aortic smooth muscle cells, PMC12290114
• Are There Common Mechanisms Between HGPS and Natural Aging?, PMC6529819
• Cabral et al., Aging Cell 2021 (mTOR reduction)
• Hong et al., Aging Cell 2024 (G608G mouse cardiac/skeletal muscle)
• Long term breeding of the Lmna G609G progeric mouse, PubMed
• Progerinin, Communications Biology 2020
• BioSpace: FDA authorizes Progerinin Phase 2a trial
• Reddy & Comai, Neonatal progeria, EJHG 2012
• Intervention for critical aortic stenosis in HGPS, PMC11079313
• Progeroid laminopathy with restrictive dermopathy-like features (LMNA p.R435C), PMC3824411
• National survey of HGPS and progeroid laminopathy in Japan, PMC12339027

Note: A small number of PMIDs above (marked "verify") are best-effort citations from general literature knowledge rather than confirmed via this session's searches; before using any specific PMID/snippet in a dismech KB entry, follow the project's mandatory verification workflow (just fetch-reference PMID:XXXX + just validate-references) rather than relying on this report's citations directly.